S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
Buffett's firm reports $44B loss but its businesses thrive
Musk says Twitter deal could move ahead with 'bot' info
Dems' climate, energy, tax bill clears initial Senate hurdle
Demand for grocery delivery cools as food costs rise
China July exports rise, with trade surplus at record-high
Shift in war's front seen as ships cleared to leave Ukraine
Venezuela, Colombia border areas hopeful as reopening looms
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
Buffett's firm reports $44B loss but its businesses thrive
Musk says Twitter deal could move ahead with 'bot' info
Dems' climate, energy, tax bill clears initial Senate hurdle
Demand for grocery delivery cools as food costs rise
China July exports rise, with trade surplus at record-high
Shift in war's front seen as ships cleared to leave Ukraine
Venezuela, Colombia border areas hopeful as reopening looms
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
Buffett's firm reports $44B loss but its businesses thrive
Musk says Twitter deal could move ahead with 'bot' info
Dems' climate, energy, tax bill clears initial Senate hurdle
Demand for grocery delivery cools as food costs rise
China July exports rise, with trade surplus at record-high
Shift in war's front seen as ships cleared to leave Ukraine
Venezuela, Colombia border areas hopeful as reopening looms
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
Buffett's firm reports $44B loss but its businesses thrive
Musk says Twitter deal could move ahead with 'bot' info
Dems' climate, energy, tax bill clears initial Senate hurdle
Demand for grocery delivery cools as food costs rise
China July exports rise, with trade surplus at record-high
Shift in war's front seen as ships cleared to leave Ukraine
Venezuela, Colombia border areas hopeful as reopening looms

ESSA Pharma (EPIX) Stock Forecast, Price & News

$3.00
-0.02 (-0.66%)
(As of 08/5/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.95
$3.06
50-Day Range
$2.48
$5.50
52-Week Range
$2.41
$21.85
Volume
213,388 shs
Average Volume
899,704 shs
Market Capitalization
$132.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.00

ESSA Pharma MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
600.0% Upside
$21.00 Price Target
Short Interest
Healthy
1.91% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.86mentions of ESSA Pharma in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$1.93 M Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.01) to ($1.18) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.47 out of 5 stars

Medical Sector

208th out of 1,283 stocks

Pharmaceutical Preparations Industry

85th out of 615 stocks

ESSA Pharma logo

About ESSA Pharma (NASDAQ:EPIX) Stock

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

Wall Street Analyst Weigh In

Separately, Piper Sandler lowered their price target on shares of ESSA Pharma from $50.00 to $20.00 in a report on Thursday, May 12th.

ESSA Pharma Price Performance

EPIX traded down $0.02 during trading hours on Friday, reaching $3.00. 213,388 shares of the stock traded hands, compared to its average volume of 899,704. ESSA Pharma has a fifty-two week low of $2.41 and a fifty-two week high of $21.85. The company has a market cap of $132.06 million, a price-to-earnings ratio of -3.49 and a beta of 1.59. The firm's fifty day simple moving average is $3.64 and its two-hundred day simple moving average is $6.03.

ESSA Pharma (NASDAQ:EPIX - Get Rating) (TSE:EPI) last posted its quarterly earnings data on Tuesday, May 10th. The company reported ($0.25) EPS for the quarter, meeting analysts' consensus estimates of ($0.25). On average, research analysts predict that ESSA Pharma will post -1.02 earnings per share for the current year.

Insider Transactions at ESSA Pharma

In other ESSA Pharma news, major shareholder Growth N. V. Biotech purchased 300,000 shares of ESSA Pharma stock in a transaction dated Monday, July 18th. The shares were bought at an average cost of $3.16 per share, for a total transaction of $948,000.00. Following the transaction, the insider now owns 5,879,583 shares in the company, valued at approximately $18,579,482.28. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, major shareholder Growth N. V. Biotech acquired 347,204 shares of the company's stock in a transaction that occurred on Thursday, July 14th. The shares were acquired at an average price of $2.79 per share, with a total value of $968,699.16. Following the acquisition, the insider now directly owns 5,337,918 shares in the company, valued at $14,892,791.22. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, major shareholder Growth N. V. Biotech acquired 300,000 shares of the company's stock in a transaction that occurred on Monday, July 18th. The stock was purchased at an average cost of $3.16 per share, for a total transaction of $948,000.00. Following the acquisition, the insider now owns 5,879,583 shares in the company, valued at $18,579,482.28. The disclosure for this purchase can be found here. In the last three months, insiders have acquired 652,091 shares of company stock worth $1,931,165. 9.90% of the stock is currently owned by insiders.

Receive EPIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ESSA Pharma and its competitors with MarketBeat's FREE daily newsletter.

EPIX Stock News Headlines

27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate. pixel
EPIX Stock Gains 11.6% on Insider Buys
27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate. pixel
ESSA Pharma Inc.(EPIX)
ESSA Pharma Inc. Common Stock (EPIX)
See More Headlines

Receive EPIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ESSA Pharma and its competitors with MarketBeat's FREE daily newsletter.

EPIX Company Calendar

Last Earnings
5/10/2022
Today
8/07/2022
Fiscal Year End
9/30/2022
Next Earnings (Estimated)
11/17/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EPIX
Employees
25
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$21.00
High Stock Price Forecast
$22.00
Low Stock Price Forecast
$20.00
Forecasted Upside/Downside
+600.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-36,810,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.41 per share

Miscellaneous

Free Float
39,658,000
Market Cap
$132.06 million
Optionable
Not Optionable
Beta
1.59

Key Executives

  • Dr. David Ross Parkinson M.D. (Age 72)
    Pres, CEO & Director
    Comp: $829.56k
  • Mr. David S. Wood C.M.A. (Age 65)
    CPA, M.B.A., MBA, CPA, CMA, Chief Financial Officer
    Comp: $532.35k
  • Mr. Peter A. Virsik M.B.A. (Age 51)
    M.S., Exec. VP & COO
    Comp: $646.75k
  • Dr. Alessandra Cesano M.D.
    Ph.D., Chief Medical Officer
  • Chandtip Chandhasin
    Exec.
  • Erica Osbourne
    Exec.
  • Erin Rudsinski
    Exec.
  • Loleta Harris
    Exec.
  • Neil Thapar
    Exec.
  • Nkengyal Barber
    Exec.













EPIX Stock - Frequently Asked Questions

Should I buy or sell ESSA Pharma stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ESSA Pharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ESSA Pharma stock.
View analyst ratings for ESSA Pharma
or view top-rated stocks.

What is ESSA Pharma's stock price forecast for 2022?

1 Wall Street research analysts have issued 1 year price targets for ESSA Pharma's stock. Their EPIX stock forecasts range from $20.00 to $22.00. On average, they predict ESSA Pharma's share price to reach $21.00 in the next year. This suggests a possible upside of 600.0% from the stock's current price.
View analysts' price targets for ESSA Pharma
or view top-rated stocks among Wall Street analysts.

How has ESSA Pharma's stock price performed in 2022?

ESSA Pharma's stock was trading at $14.20 at the start of the year. Since then, EPIX stock has decreased by 78.9% and is now trading at $3.00.
View the best growth stocks for 2022 here
.

Are investors shorting ESSA Pharma?

ESSA Pharma saw a decrease in short interest during the month of July. As of July 15th, there was short interest totaling 331,400 shares, a decrease of 85.2% from the June 30th total of 2,240,000 shares. Based on an average daily trading volume, of 412,600 shares, the short-interest ratio is presently 0.8 days. Approximately 1.9% of the shares of the stock are short sold.
View ESSA Pharma's Short Interest
.

When is ESSA Pharma's next earnings date?

ESSA Pharma is scheduled to release its next quarterly earnings announcement on Thursday, November 17th 2022.
View our earnings forecast for ESSA Pharma
.

How were ESSA Pharma's earnings last quarter?

ESSA Pharma Inc. (NASDAQ:EPIX) posted its quarterly earnings data on Tuesday, May, 10th. The company reported ($0.25) EPS for the quarter, meeting the consensus estimate of ($0.25).

What other stocks do shareholders of ESSA Pharma own?

What is ESSA Pharma's stock symbol?

ESSA Pharma trades on the NASDAQ under the ticker symbol "EPIX."

Who are ESSA Pharma's major shareholders?

ESSA Pharma's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Candriam S.C.A. (1.29%). Company insiders that own ESSA Pharma stock include David Ross Parkinson, Franklin M Berger and Growth N V Biotech.
View institutional ownership trends for ESSA Pharma
.

How do I buy shares of ESSA Pharma?

Shares of EPIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ESSA Pharma's stock price today?

One share of EPIX stock can currently be purchased for approximately $3.00.

How much money does ESSA Pharma make?

ESSA Pharma (NASDAQ:EPIX) has a market capitalization of $132.06 million. The company earns $-36,810,000.00 in net income (profit) each year or ($0.86) on an earnings per share basis.

How many employees does ESSA Pharma have?

ESSA Pharma employs 25 workers across the globe.

How can I contact ESSA Pharma?

ESSA Pharma's mailing address is 999 WEST BROADWAY SUITE 720, VANCOUVER A1, V5Z 1K5. The official website for ESSA Pharma is www.essapharma.com. The company can be reached via phone at 778-331-0962, via email at alada@troutgroup.com, or via fax at 604-738-4080.

This page (NASDAQ:EPIX) was last updated on 8/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.